PM
CRL icon

Pembroke Management’s Charles River Laboratories CRL Stock Holding History

Pembroke Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-35,633
Closed -$13.4M – 70
2021
Q4 		$13.4M Sell
35,633
-34,381
-49% -$13.4M 0.98% 43
2021
Q3 		$28.9M Buy
70,014
+255
+0.4% +$106K 2.18% 19
2021
Q2 		$25.8M Sell
69,759
-14,302
-17% -$4.78M 2.02% 20
2021
Q1 		$24.4M Sell
84,061
-32,076
-28% -$8.92M 2.03% 19
2020
Q4 		$29M Sell
116,137
-9,202
-7% -$2.19M 2.43% 13
2020
Q3 		$28.4M Buy
125,339
+9
+0% +$1.87K 3.09% 5
2020
Q2 		$21.9M Sell
125,330
-7,258
-5% -$1.16M 2.57% 12
2020
Q1 		$16.7M Buy
132,588
+14,491
+12% +$2.17M 2.66% 10
2019
Q4 		$18M Sell
118,097
-16,943
-13% -$2.35M 1.53% 31
2019
Q3 		$17.9M Buy
135,040
+31,689
+31% +$4.25M 1.94% 24
2019
Q2 		$14.7M Sell
103,351
-884
-0.8% -$120K 1.55% 34
2019
Q1 		$15.1M Buy
104,235
+34,900
+50% +$4.59M 1.64% 28
2018
Q4 		$7.85M Sell
69,335
-18,450
-21% -$2.31M 1.07% 41
2018
Q3 		$11.8M Sell
87,785
-32,100
-27% -$3.96M 1.21% 39
2018
Q2 		$13.5M Sell
119,885
-3,800
-3% -$411K 1.38% 35
2018
Q1 		$13.2M Buy
123,685
+46,150
+60% +$4.97M 1.4% 33
2017
Q4 		$8.49M Sell
77,535
-50,000
-39% -$5.44M 0.87% 49
2017
Q3 		$13.8M Sell
127,535
-92,800
-42% -$9.53M 1.35% 40
2017
Q2 		$22.3M Sell
220,335
-51,400
-19% -$4.73M 1.98% 16
2017
Q1 		$24.4M Buy
271,735
+15,900
+6% +$1.35M 2.4% 13
2016
Q4 		$19.5M Buy
255,835
+29,300
+13% +$2.23M 1.99% 18
2016
Q3 		$18.9M Sell
226,535
-90,900
-29% -$7.62M 1.87% 23
2016
Q2 		$26.2M Buy
317,435
+16,000
+5% +$1.32M 2.39% 14
2016
Q1 		$22.9M Sell
301,435
-13,000
-4% -$962K 2.01% 24
2015
Q4 		$25.3M Sell
314,435
-32,900
-9% -$2.37M 2.04% 21
2015
Q3 		$22.1M Buy
347,335
+87,235
+34% +$6.26M 1.64% 32
2015
Q2 		$18.3M Buy
260,100
+30,200
+13% +$2.23M 1.16% 38
2015
Q1 		$18.2M Buy
229,900
+28,500
+14% +$2.1M 1.15% 37
2014
Q4 		$12.8M Buy
+201,400
New +$12.6M 0.79% 39

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Pembroke Management's CRL Position: Q1 2022 in Review

Pembroke Management sold out of Charles River Laboratories (CRL) in Q1 2022, closing a stake of 35,633 shares — an estimated $13.4M sold.

Pembroke Management first reported a position in CRL in Q4 2014 and held it in 29 quarters. The position peaked at $29M in Q4 2020. 644 funds tracked by Wall St. Rank hold CRL as of Q1 2022.

  • Pembroke Management reported no remaining Charles River Laboratories position as of Q1 2022 after selling out during the quarter.
  • Pembroke Management sold 35,633 Charles River Laboratories shares in Q1 2022, an estimated $13.4M.
  • Pembroke Management first reported a position in Charles River Laboratories in Q4 2014 and held it in 29 quarters.
  • Pembroke Management's Charles River Laboratories position peaked at $29M in Q4 2020.
  • 644 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2022.

Based on Pembroke Management's 13F filing for Q1 2022, filed 6 May 2022.